Biotech's fast-revving engine of the past decade has pulled in for a tuneup.Last month's J.P. Morgan Healthcare Conference served as a way for investors to push the check-engine light. If the engine starts to sound smooth to investors, maybe they'll jump in for a ride.
On the readout side, Bridge Bio has at least two big events this year: one in late February or early March for a mid-stage study of its oral drug infigratinib to treat achondroplasia, a bone growth disorder that is the most common type of short-limbed dwarfism; the other is Phase III trial data in July for acoramidis, its experimental orally administered treatment for transthyretin amyloidosis, a condition where clumps of protein build up in the heart.
"A substantial number of companies need to tap financial markets this year," Kumar said."That puts the focus on this year and 'how do I get people to keep their eyes on this.'" But around Labor Day last year, Dice needed to make a decision on whether to hire more people for a potential mid-stage clinical trial while not knowing whether the Phase I study data coming in October would be good or bad."Understaffing I can deal with — you just hire more people," Judice said.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: nbcbayarea - 🏆 596. / 51 続きを読む »